Gene therapy using Aβ variants for amyloid reduction

Kyung Won Park, Caleb A. Wood, Jun Li, Bethany C. Taylor, Sae Woong Oh, Nicolas L. Young, Joanna L. Jankowsky

Research output: Contribution to journalArticlepeer-review

Abstract

Numerous aggregation inhibitors have been developed with the goal of blocking or reversing toxic amyloid formation in vivo. Previous studies have used short peptide inhibitors targeting different amyloid β (Aβ) amyloidogenic regions to prevent aggregation. Despite the specificity that can be achieved by peptide inhibitors, translation of these strategies has been thwarted by two key obstacles: rapid proteolytic degradation in the bloodstream and poor transfer across the blood-brain barrier. To circumvent these problems, we have created a minigene to express full-length Aβ variants in the mouse brain. We identify two variants, F20P and F19D/L34P, that display four key properties required for therapeutic use: neither peptide aggregates on its own, both inhibit aggregation of wild-type Aβ in vitro, promote disassembly of pre-formed fibrils, and diminish toxicity of Aβ oligomers. We used intraventricular injection of adeno-associated virus (AAV) to express each variant in APP/PS1 transgenic mice. Lifelong expression of F20P, but not F19D/L34P, diminished Aβ levels, plaque burden, and plaque-associated neuroinflammation. Our findings suggest that AAV delivery of Aβ variants may offer a novel therapeutic strategy for Alzheimer's disease. More broadly our work offers a framework for identifying and delivering peptide inhibitors tailored to other protein-misfolding diseases.

Original languageEnglish (US)
Pages (from-to)2294-2307
Number of pages14
JournalMolecular Therapy
Volume29
Issue number7
DOIs
StatePublished - Jul 7 2021

Keywords

  • APP/PS1 mouse
  • P0 injection
  • amyloid
  • peptide inhibitor
  • viral vector

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Gene therapy using Aβ variants for amyloid reduction'. Together they form a unique fingerprint.

Cite this